Revance Announces Leadership Succession Plan to Support Next Phase of Growth and Innovation

Founder and CEO Jeff Bedard Transitioning to Founder and Executive Chairman; Nadeem Moiz Appointed as Incoming Chief Executive Officer

NASHVILLE, Tenn., May 21, 2025 /PRNewswire/ -- Revance, a fast-growing global leader in aesthetics and skincare, today announced a leadership transition to support the Company's next chapter of growth and innovation, as it builds toward becoming the most dynamic, science-backed, operationally disciplined, and customer-focused aesthetics and skincare company in the industry. Jeff Bedard, who founded the company 25 years ago with a vision to revolutionize skincare, will transition from Founder and Chief Executive Officer to Founder and Executive Chairman of the Board. Nadeem Moiz, President, COO and CFO, whose operational leadership has been instrumental in the Company's recent growth and successful integration, will become Chief Executive Officer effective October 1, 2025.

"This thoughtfully planned transition recognizes the outstanding company and exceptional legacy that Jeff has built," said Hildred Co-Founders and Managing Partners Andrew Goldman and David Solomon. "His vision, determination, and leadership have created the high growth differentiated portfolio and entrepreneurial culture that define Revance today."

As Executive Chairman, Bedard will remain actively involved, working closely with Moiz to ensure continuity in Revance's customer and patient-first approach, while supporting long-term strategy and mentoring the leadership team. In their new roles, Moiz will continue to report to Bedard.

"We would not be here without Jeff's vision and determination to make the Company what it is today, and we are excited to have him continuing to lead the company as Founder and Executive Chairman," said Goldman and Solomon. "We believe Nadeem's knowledge of the business, deep operational and financial acumen, and understanding of the dynamic skincare and aesthetics markets make him the ideal candidate to execute on our go-forward strategy as we become a global leader in injectables, skin quality and skincare solutions."

The long-term succession plan is a natural next step in the evolution of the newly combined company. Earlier this year, Crown Laboratories acquired Revance Therapeutics, creating a comprehensive portfolio that spans from everyday skincare needs to advanced aesthetics treatments. In March, the Company announced it would begin operating under the name Revance, bringing together award-winning consumer brands like PanOxyl^®, Blue Lizard^® and StriVectin^®, along with innovative aesthetics solutions including DAXXIFY^® (DaxibotulinumtoxinA-lanm), the RHA^® Collection by Teoxane SA and SkinPen^®.

In his new role as Founder and Executive Chairman, Bedard will have broad strategic oversight of the business and will continue to leverage his deep industry relationships to identify strategic partnerships and acquisitions to bolster the portfolio, while continuing to work closely with key customers.

"I founded Crown 25 years ago with a vision to develop a unique portfolio of safe and effective scientific solutions for life-long healthy skin. Alongside my talented team members, we have achieved this goal and positioned the company for our next chapter of success, with the addition and integration of Revance Therapeutics' innovative aesthetics solutions," said Bedard. "Now, as we look to the future, I am thrilled to take on the role of Executive Chairman and have Nadeem step into the CEO position to help further accelerate our growth for years to come."

Moiz joined the company in 2022 as Chief Operating Officer and Chief Financial Officer, and his role was expanded to President in 2024. His leadership has driven a scalable business model to support growth, efficiency and innovation. Moiz also has a deep understanding of operational intricacies and strategic financial management. Under his guidance, Revance is ready to execute its long-term strategy with continued operational discipline while expanding customer relationships across its expanding global footprint.

"I am energized about the future of Revance and appreciative of the trust placed in me by Jeff and the Board to guide the company forward," said Moiz. "I am excited to apply over 25 years of experience across strategy, operations and finance to solidify Revance's leading position in the marketplace. We will also continue our market leading innovation and commercialization of science-based skincare and aesthetics products."

About Revance

Revance is a fast-growing, highly acquisitive, global aesthetics and skincare company committed to delivering innovative aesthetics and market-leading skincare solutions across every stage of life. With a differentiated portfolio and market position, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and the commercialization of new products and treatments. Focused on skin science for life, Revance continues to expand its global footprint, with distribution spanning 60 countries and a significant opportunity to enter new markets.

Revance's balanced portfolio includes innovative products in the aesthetics space such as DAXXIFY^® (DaxibotulinumtoxinA-lanm) for injection, the RHA^® Collection of dermal fillers by Teoxane SA, and SkinPen^®, an industry-leading microneedling device. RHA^® technology is proprietary to and manufactured in Switzerland by Teoxane SA, and Revance is an independent distributor of Teoxane SA to supply the RHA Collection of dermal fillers to the U.S. market. In addition, its consumer skincare portfolio includes leading brands such as PanOxyl^®, Blue Lizard^®, StriVectin^® and BIOJUVE^®.

RHA^® is a trademark of TEOXANE SA. 

Learn more at Revance.com, RevanceAesthetics.com, CrownLaboratories.com, and CrownAesthetics.com.

SOURCE Revance